Eli Lilly & Co. - LLY STOCK NEWS

Eli Lilly and Company (LLY) announced that mirikizumab achieved primary and all key secondary endpoints in the Phase 3 LUCENT-1 trial for moderate to severe ulcerative colitis, demonstrating significant clinical remission and symptom improvement by Week 12. The study reported statistically significant results (p<0.0001) and rapid symptom relief within four weeks. Patient safety profile remained consistent with prior studies. Ongoing maintenance study LUCENT-2 aims to further evaluate mirikizumab's long-term effects. Full results will be disclosed in future publications.

Eli Lilly (NYSE: LLY) presented Phase 2 TRAILBLAZER-ALZ results, confirming that donanemab significantly slows cognitive decline in early Alzheimer's patients. The study demonstrated a 32% decline in the Integrated Alzheimer's Disease Rating Scale compared to placebo at 76 weeks, with notable amyloid plaque clearance. Secondary endpoints showed a 20-40% decline across various cognitive measures. Despite a 26.7% incidence of amyloid-related imaging abnormalities, ongoing discussions with regulators are promising, enhancing donanemab's potential for disease modification.

Eli Lilly and Company (NYSE: LLY) announced participation in the 2021 AACR Annual Meeting with presentations from its oncology portfolio. Highlights include data on Retevmo® (selpercatinib) for RET fusion-positive cancers beyond lung and thyroid cancers. The company will also showcase preclinical data for a selective estrogen receptor degrader, a BCL2 inhibitor, and next-generation KRAS-G12C and RET inhibitors. Retevmo received FDA’s Accelerated Approval last May, and further studies are aimed at expanding its application in various cancer types.

Eli Lilly reports promising results from the BLAZE-1 Phase 3 study, showing that bamlanivimab and etesevimab significantly lower COVID-19 hospitalizations and deaths in high-risk patients. Among 769 participants, the combination treatment led to an 87% reduction in events compared to placebo. No deaths occurred in the treatment group, while 15 occurred in the placebo group. The FDA and EMA support the emergency use of these treatments, emphasizing their potential as a life-saving option against COVID-19, especially with emerging variants.

Eli Lilly (NYSE: LLY) will present new data from ten studies at the virtual AD/PD 2021 conference from March 9-14, 2021. The TRAILBLAZER-ALZ phase 2 study demonstrated that donanemab significantly slowed cognitive decline in early symptomatic Alzheimer's patients compared to placebo. The conference will highlight Lilly's commitment to developing disease-modifying therapies and diagnostics for Alzheimer's disease, which currently affects over 50 million globally. The company aims to enhance early diagnosis and treatment options for this complex illness.

Eli Lilly and Company (NYSE: LLY) announced the retirement of two executive committee members: Myles O'Neill, senior VP of manufacturing operations, effective May 2, 2021, and Melissa Barnes, chief ethics and compliance officer, effective June 27, 2021. Edgardo Hernandez will succeed O'Neill, bringing extensive manufacturing experience, while Alonzo Weems will take over for Barnes, enhancing compliance and risk management. CEO David Ricks highlighted the executives' legacies and the potential growth under the new leadership.

Eli Lilly and Company (NYSE: LLY) has entered a research collaboration with Biolojic Design Ltd. to explore a novel antibody-based therapy for diabetes. The agreement includes research fees and the potential for Biolojic to earn up to $121 million in development milestones. Lilly's approach involves leveraging Biolojic's AI-driven multibody platform, designed to enhance therapeutic precision. Both companies aim to innovate diabetes treatment, with no changes to Lilly's 2021 financial guidance anticipated from this partnership.

Eli Lilly and Company (NYSE: LLY) will participate in the Barclays Global Healthcare Conference on March 9, 2021. Patrik Jonsson, senior vice president and chief customer officer, will engage in a virtual fireside chat at 9:45 a.m. ET. A live audio webcast will be available on Lilly's Investor website, and a replay will be accessible for about 90 days. Lilly is dedicated to creating high-quality medicines and improving disease management globally. For more information, visit www.lilly.com.

Eli Lilly announced a positive scientific opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for bamlanivimab alone and in combination with etesevimab. These therapies are recommended for treating COVID-19 in patients aged 12 and older at high risk of severe disease, who do not require supplemental oxygen. Data from the BLAZE-1 trial indicated a 70% reduction in hospitalizations. Lilly aims to provide affordable access globally, especially in low- and middle-income countries, while emphasizing that these treatments are not FDA-approved and carry potential risks.